Cellectar Biosciences Q3 2026 earnings
Operating expenses increased 34% YoY to $8.1M, and the net loss widened to $7.97M despite a $50K warrant loss reversal.
Headline numbers
not stated in the 8-K
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $8.1M (+67% YoY)
- One-offs in the quarter Warrant loss reversal ($50K)
- Effective tax rate not stated in the 8-K
- Non-GAAP bridge not stated in the 8-K
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash and cash equivalents | $24.58M | $33.99M | $13.20M | -28% |
| Total current assets | $25.71M | $34.88M | $14.04M | -26% |
| Total assets | $29.74M | $36.64M | $14.98M | -19% |
Guidance
not stated in the 8-K
What drove it
- Revenue story No revenue reported.
- EPS story Net loss per share widened due to higher operating expenses and a warrant loss reversal, partially offset by higher interest income.
- One-off check Warrant loss reversal of $50K (vs $294K gain in prior year).
The good
- Interest income increased 59% YoY to $179K.
The bad
- Research and development expenses increased 115% YoY to $5.44M.
- Net loss widened 44% YoY to $7.97M.
- Cash and cash equivalents declined 28% QoQ to $24.58M.
The ugly
- none
Open questions
- What drove the 115% YoY increase in R&D expenses?
- What is the specific use of the $2.28M contracted research organization deposit?
Full release
Cellectar Biosciences (CLRB) earnings release, November 10, 2026
Cellectar Biosciences
Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in
Waldenström macroglobulinemia (WM)
On track to dose first patients in the confirmatory Phase 3 trial of iopofosine I 131 in first quarter 2027 and to file for accelerated approval with the FDA in 1H 2027
Published case study of iopofosine I 131 highlighting a complete response lasting more than eight years in heavily pretreated diffuse large B-cell lymphoma patient
Company to host webcast and conference call at 8:30 AM ET today
FLORHAM PARK, N.J., November 10,
2026 (GLOBE NEWSWIRE)
-- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a corporate update.
“We remain focused on executing the clinical, regulatory and operational activities necessary to position iopofosine I 131 for potential registration and commercialization in Waldenström macroglobulinemia, and we believe our third quarter progress represents a significant step toward that goal,” said James Caruso, president and chief executive officer of Cellectar Biosciences. “The new sub-analysis efficacy data presented at the International Workshop for Waldenström Macroglobulinemia (IWWM) further strengthen our confidence in the clinical profile of iopofosine I 131, demonstrating high response rates, durable outcomes and a favorable safety profile in a difficult-to-treat post-BTK inhibitor patient population, which is the same patient population being evaluated in our Phase 3 confirmatory clinical trial.”
“To further maximize the long-term value of the program, we have initiated our Phase 1b dosimetry trial, which we believe offers an important opportunity to further characterize iopofosine I 131 across WM treatment settings, including first and second line. With these trials underway, a planned NDA submission in the first half of 2027, and continued advancement of our broader PDC pipeline, we believe Cellectar is entering a period of significant value creation with multiple meaningful milestones in 2027,” continued Mr. Caruso.
Third Quarter 2026 and Recent Corporate
Highlights
2026 Financial Highlights
Conference Call & Webcast
Details
Cellectar management will host a conference call and webcast today, November 10, 2026, at 8:30 AM Eastern Time to discuss these results and answer questions. Stockholders and other interested parties may participate in the conference call by dialing 1-800-717-1738. A live webcast of the conference call can be accessed in the “Events & Presentations” section of Cellectar’s website at www.cellectar.com. A recording of the webcast will be available and archived on the Company’s website for approximately 90 days.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug
Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b trial is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two
Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.
Cellectar is also developing CLR 121125
(CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b trial for TNBC, which will determine the recommended dose for the subsequent Phase
2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.
In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit https://www.cellectar.com/ or join the conversation by liking and following us on the company’s social media channels:
X,
LinkedIn, and
Facebook.
Forward Looking Statements Disclaimer
Financial statements
Income Statement
Three Months Ended September 30, — (Unaudited)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| OPERATING EXPENSES: | ||||
| Research and development | 5,435,796 | 2,523,305 | 13,000,408 | 8,340,200 |
| General and administrative | 2,668,219 | 2,327,391 | 8,093,560 | 8,949,015 |
| Total operating expenses | 8,104,015 | 4,850,696 | 21,093,968 | 17,289,215 |
| LOSS FROM OPERATIONS | -8,104,015 | -4,850,696 | -21,093,968 | -17,289,215 |
| OTHER INCOME (EXPENSE): | ||||
| Gain (loss) on valuation of warrants | -50,000 | 294,276 | 159,000 | 455,874 |
| Interest income | 179,272 | 112,543 | 375,627 | 337,525 |
| Total other income | 129,272 | 406,819 | 534,627 | 793,399 |
| NET LOSS | -7,974,743 | -4,443,877 | -20,559,341 | -16,495,816 |
| NET LOSS PER SHARE — BASIC & DILUTED | -0.46 | -1.41 | -1.81 | -7.82 |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING — BASIC & DILUTED | 17,462,898 | 3,162,040 | 11,360,054 | 2,108,234 |
Balance Sheet
September 30, — (Unaudited)
| September 30, – 2026 | December 31, – 2025 | |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | 24,582,115 | 13,196,033 |
| Prepaid expenses and other current assets | 1,130,854 | 842,432 |
| Total current assets | 25,712,969 | 14,038,465 |
| Property, plant & equipment, net | 268,905 | 549,405 |
| Operating lease right-of-use asset | 1,384,274 | 360,671 |
| Contracted research organization deposit | 2,282,595 | |
| Other long-term assets | 94,520 | 29,780 |
| TOTAL ASSETS | 29,743,263 | 14,978,321 |
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued liabilities | 5,729,302 | 4,423,548 |
| Warrant liability | 67,000 | 226,000 |
| Lease liability, current | 1,318 | 100,189 |
| Total current liabilities | 5,797,620 | 4,749,737 |
| Lease liability, net of current portion | 1,530,277 | 309,397 |
| TOTAL LIABILITIES | 7,327,897 | 5,059,134 |
| MEZZANINE EQUITY: | ||
| Series D preferred stock, 111.11 shares authorized, 0.00 and 111.11 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 1,382,023 | |
| STOCKHOLDERS’ EQUITY: | ||
| Series E-2 preferred stock, 1,225 shares authorized; 0.00 and 35.60 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 520,778 | |
| Common stock, $0.00001 par value; 170,000,000 shares authorized; 10,039,183 and 4,240,129 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 100 | 42 |
| Additional paid-in capital | 312,108,109 | 277,149,844 |
| Accumulated deficit | -289,692,843 | -269,133,500 |
| Total stockholders’ equity | 22,415,366 | 8,537,164 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 29,743,263 | 14,978,321 |
Cash Flow
From the 10-Q · Nine Months Ended — (UNAUDITED)
| Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | -20,559,341 | -16,495,816 |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | -39,225 | 164,136 |
| Stock-based compensation expense | 1,398,448 | 1,695,916 |
| Change in operating lease right-of-use asset | 95,636 | 56,033 |
| Change in fair value of warrants | -159,000 | -455,874 |
| Changes in: | ||
| Prepaid expenses and other current assets | 34,680 | -105,744 |
| Lease liability | 2,770 | -62,074 |
| Accounts payable and accrued liabilities | 1,305,754 | -3,570,658 |
| Other assets | -2,347,336 | |
| Cash used in operating activities | -20,267,614 | -18,774,081 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property, plant & equipment | -3,378 | |
| Cash used in investing activities | -3,378 | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from exercise of warrants, net of issuance costs (Note 2) | 7 | 2,251,380 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs (Note 2) | 31,657,067 | 5,788,380 |
| Issuance of common stock in connection with exercise of pre-funded warrants | 3 | |
| Cash provided by financing activities | 31,657,074 | 8,039,763 |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 11,386,082 | -10,734,318 |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 13,196,033 | 23,288,607 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | 24,582,115 | 12,554,289 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Conversion of preferred stock to common stock | 1,902,801 | $— |
| Value of warrants issued to placement agent | 1,473,793 | $— |
| Right of use asset obtained in exchange for operating lease liability | 1,119,239 | $— |
| Settlement of warrants to equity | $— | 462,760 |
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate," "continue,"
"plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements... (truncated) future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31,
2025, and our Form 10-Q for the quarterly period ended September 30, 2026. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
INVESTORS:
Anne Marie Fields
Precision AQ
212-362-1200 annemarie.fields@precisionaq.com
+++ TABLES FOLLOW
+++
CELLECTAR BIOSCIENCES, INC.